A prospective multicenter observational study evaluating the risk of periendoscopic events in patients using anticoagulants: the Osaka GIANT Study

Abstract

Background and study aims An increasing number of patients have been using anticoagulants including anti-vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs); however, in patients using anticoagulants, limited data are available with regard to the risks of gastrointestinal bleeding and thromboembolic events during the peri-endoscopic period. We aimed to evaluate the peri-endoscopic bleeding and thrombotic risks in patients administered VKAs or DOACs.

Patients and methods Consecutive patients using anticoagulants who underwent endoscopic biopsy, mucosal resection, or submucosal dissection were prospectively enrolled across 11 hospitals. The primary outcome assessed was difference in incidence of post-procedural gastrointestinal bleeding in patients using VKAs and DOACs. Duration of hospitalization and peri-procedural thromboembolic events were also compared.

Results We enrolled 174 patients using VKAs and 37 using DOACs. In total, 16 patients using VKA were excluded from the analysis because of cancellation of endoscopic procedures and contraindications to the use of DOACs; 128 (81 %) patients using VKAs and 17 (46 %) using DOACs received heparin-bridging therapy (HB). The rate of post-procedural gastrointestinal bleeding in DOAC users was similar to that in VKA users (16.2 % vs. 16.4 %, P = 1.000). Duration of hospitalization was significantly longer in patients using VKAs than in those using DOACs (median 15 vs. 7 days, P < 0.0001). Myocardial infarction occurred during pre-endoscopic HB in one patient using VKAs.

Conclusion DOAC administration showed similar post-procedural gastrointestinal bleeding risk to VKA administration in patients undergoing endoscopic procedures, but it shortened the hospital stay.

^* These authors contributed equally to the study.

• References

• 1 Yaghi S, Kamel H, Elkind MS. Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke. Neurology 2015; 85: 1078-1084
• 2 Nagata N, Niikura R, Aoki T. et al. Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. J Gastroenterol 2015; 50: 1079-1086
• 3 Fujita M, Shiotani A, Murao T. et al. Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics. Dig Endosc 2015; 27: 25-29
• 4 Sterne JA, Bodalia PN, Bryden PA. et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2017; 21: 1-386
• 5 Acosta RD, Abraham NS, Chandrasekhara V. et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83: 3-16
• 6 Kaplan RC, Heckbert SR, Koepsell TD. et al. Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc 2001; 49: 126-133
• 7 Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610-1616
• 8 Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003; 61: 964-968
• 9 Fujimoto K, Fujishiro M, Kato M. et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014; 26: 1-14
• 10 Veitch AM, Baglin TP, Gershlick AH. et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008; 57: 1322-1329
• 11 Anderson MA, Ben-Menachem T, Gan SI. et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060-1070
• 12 Yoshio T, Nishida T, Kawai N. et al. Gastric ESD under heparin replacement at high-risk patients of thromboembolism is technically feasible but has a high risk of delayed bleeding: Osaka University ESD Study Group. Gastroenterol Res Pract 2013; 2013: 365830
• 13 Inoue T, Nishida T, Maekawa A. et al. Clinical features of post-polypectomy bleeding associated with heparin bridge therapy. Dig Endosc 2014; 26: 243-249
• 14 Kubo T, Yamashita K, Onodera K. et al. Heparin bridge therapy and post-polypectomy bleeding. World J Gastroenterol 2016; 22: 10009-10014
• 15 Siegal D, Yudin J, Kaatz S. et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639
• 16 Turun S, Banghua L, Yuan Y. et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res 2011; 127: 525-534
• 17 Cao YB, Zhang JD, Shen H. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010; 66: 1099-1108
• 18 Neumann I, Rada G, Claro JC. et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012; 156: 710-719
• 19 Levy JH, Spyropoulos AC, Samama CM. et al. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv 2014; 7: 1333-1351
• 20 Chatterjee P, Weitz JI. Assessment and management of gastrointestinal hemorrhage in the setting of direct oral anticoagulants: the hematology perspective. Am J Gastroenterol Suppl 2016; 3: 29-35
• 21 Veitch AM, Vanbiervliet G, Gershlick AH. et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2016; 48: 1-18
• 22 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
• 23 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
• 24 Pamukcu B, Lip GY, Lane DA. Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age Ageing 2010; 39: 533-535
• 25 Robins JM, Rotnitzky A, Zhao LP. Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 1994; 427: 846-866
• 26 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009; 361: 1139-1151
• 27 Holster IL, Valkhoff VE, Kuipers EJ. et al. New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis. Gastroenterology 2013; 145: 105-112.e115
• 28 Yoshio T, Nishida T, Hayashi Y. et al. Clinical problems with antithrombotic therapy for endoscopic submucosal dissection for gastric neoplasms. World J Gastrointest Endosc 2016; 8: 756-762
• 29 Douketis JD, Spyropoulos AC, Kaatz S. et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. NEJM 2015; 373: 823-833
• 30 Kato M, Uedo F, Hokimoto S. et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Supplement revision of the use of anticoagulant drugs including direct oral anticoagulant drugs (DOACs). Gastroenterol Endosc 2017; 59: 1547-1558 (in Japanese)
• 31 Heublein V, Pannach S, Daschkow K. et al. Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. J Gastroenterol 2018; 53: 236-246
• 32 Goldstein JL, Larson LR, Yamashita BD. et al. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study. Am J Gastroenterol 2001; 96: 2360-2366
• 33 Jaff MR. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to “bridge” patients instead of intravenous unfractionated heparin?. Catheter Cardiovasc Interv 2009; 74 (Suppl. 01) S17-S21